Altimmune (ALT) Asset Writedowns and Impairment (2016 - 2026)
Altimmune (ALT) posted quarterly Asset Writedowns and Impairment of $709000.0 for Q1 2026, down 78.52% quarter-over-quarter from $3.3 million in Q4 2021.
Powered by 
Analysis
Altimmune (ALT) Asset Writedowns and Impairment (2016 - 2026) Analysis & Trends
Altimmune (ALT) has reported Asset Writedowns and Impairment for 5 consecutive years, with $709000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Asset Writedowns and Impairment changed N/A year-over-year to $709000.0; the TTM figure through Mar 2026 stood at $12.1 million (changed N/A YoY), while the FY2023 annual figure was $12.4 million, changed N/A from the prior year.
- Asset Writedowns and Impairment retreated to $709000.0 in Q1 2026 per ALT's latest filing, from $3.3 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $709000.0 in Q1 2026 and bottomed at $709000.0 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Altimmune | 636.07 Mn | 636.07 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 800,000.00 |
| Mar 31, 2026 | 700,000.00 |
| Dec 31, 2021 | 3.30 Mn |
| Jun 30, 2021 | 8.07 Mn |
| Sep 30, 2019 | 1.00 Mn |
| Dec 31, 2018 | 24.45 Mn |
| Mar 31, 2018 | 490,676.00 |
| Dec 31, 2016 | 2.56 Mn |